Identification
- Summary
Zinc sulfate is a drug used to replenish low levels of zinc or prevent zinc deficiency, or to test for zinc deficiency.
- Brand Names
- Anodan-HC, Anusol, Egozinc, Multitrace-4, Multitrace-5, Proctodan-HC, Rectogel, Riva-sol HC, Tandem Plus
- Generic Name
- Zinc sulfate
- DrugBank Accession Number
- DB09322
- Background
Zinc sulfate is the inorganic compound with the formula ZnSO4 and historically known as "white vitriol". It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Zinc sulfate (DB09322)
- Weight
- Average: 161.472
Monoisotopic: 159.880875756 - Chemical Formula
- O4SZn
- Synonyms
- Zinc sulfate (anhydrous)
- Zinc sulfate anhydrous
- Zinc sulfate, anhydrous
- Zinc sulphate
- Zinc sulphate anhydrous
- Zinc sulphate, anhydrous
Pharmacology
- Indication
This medication is a mineral used to treat or prevent low levels of zinc alone and together with oral rehydration therapy (ORT). It is also used as a topical astringent. Zinc Sulfate Injection, USP is indicated for use as a supplement to intravenous solutions given for TPN.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination for symptomatic treatment of Dry eyes Combination Product in combination with: Phenylephrine (DB00388) ••• ••• •••••••• • ••••• Used in combination for symptomatic treatment of Local pain Combination Product in combination with: Heparin (DB01109) •••••••••••• ••• Used in combination for symptomatic treatment of Local swelling Combination Product in combination with: Heparin (DB01109) •••••••••••• ••• Used in combination for symptomatic treatment of Local itching Combination Product in combination with: Heparin (DB01109) •••••••••••• ••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Zinc has been identified as a cofactor for over 70 different enzymes, including alkaline phosphatase, lactic dehydrogenase and both RNA and DNA polymerase. Zinc facilitates wound healing, helps maintain normal growth rates, normal skin hydration and the senses of taste and smell.
- Mechanism of action
Zinc inhibits cAMP-induced, chloride-dependent fluid secretion by inhibiting basolateral potassium (K) channels, in in-vitro studies with rat ileum. This study has also shown the specificity of Zn to cAMP-activated K channels, because zinc did not block the calcium (Ca)-mediated K channels. As this study was not performed in Zn-deficient animals, it provides evidence that Zn is probably effective in the absence of Zn deficiency. Zinc also improves the absorption of water and electrolytes, improves regeneration of the intestinal epithelium, increases the levels of brush border enzymes, and enhances the immune response, allowing for a better clearance of the pathogens.
- Absorption
Approximately 20 to 30% of dietary zinc is absorbed, primarily from the duodenum and ileum. The amount absorbed is dependent on the bioavailability from food. Zinc is the most bioavailable from red meat and oysters. Phytates may impair absorption by chelation and formation of insoluble complexes at an alkaline pH. After absorption, zinc is bound in the intestine to the protein metallothionein. Endogenous zinc can be reabsorbed in the ileum and colon, creating an enteropancreatic circulation of zinc.
- Volume of distribution
After absorption zinc is bound to protein metallothionein in the intestines. Zinc is widely distributed throughout the body. It is primarily stored in RBCs, WBCs, muscles, bones, Skin, Kidneys, Liver, Pancreas, retina, and prostate.
- Protein binding
Zinc is 60% bound to albumin; 30 to 40% bound to alpha-2 macroglobulin or transferrin; and 1% bound to amino acids, primarily histidine and cysteine.
- Metabolism
- Not Available
- Route of elimination
Primarily fecal (approximately 90%); to a lesser extent in the urine and in perspiration.
- Half-life
3 hours
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Human : TDLo ( Oral) 45mg/kg/7D-C : Normocytic anemia, pulse rate increase without fall inBP Human: TDLo (oral) 106mg/kg : Hypermotylity, diarrhea Mouse ; LD50 Oral : 245mg/kg Mouse : LD50 : subcutaneous : 781mg/kg
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareCarbamazepine Zinc sulfate can cause a decrease in the absorption of Carbamazepine resulting in a reduced serum concentration and potentially a decrease in efficacy. Ceftibuten Zinc sulfate can cause a decrease in the absorption of Ceftibuten resulting in a reduced serum concentration and potentially a decrease in efficacy. Cephalexin Zinc sulfate can cause a decrease in the absorption of Cephalexin resulting in a reduced serum concentration and potentially a decrease in efficacy. Cinoxacin Zinc sulfate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Ciprofloxacin Zinc sulfate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. - Food Interactions
- Avoid milk and dairy products. Separate the use of zinc from these products by at least 2 hours before administration. Separate for 2 hours after administration if these products also contain phosphorus.
- Do not take with bran and high fiber foods. For optimal absorption, take zinc at least 2 hours before or after eating high-fiber foods.
- Take on an empty stomach. Take at least 1 hour before and 2 hours after eating for optimal absorption. Zinc can be taken with food to reduce gastrointestinal upset.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Zinc sulfate heptahydrate N57JI2K7WP 7446-20-0 RZLVQBNCHSJZPX-UHFFFAOYSA-L Zinc sulfate hexahydrate Not Available 13986-24-8 QWCKCWSBAUZZLF-UHFFFAOYSA-L Zinc sulfate monohydrate PTX099XSF1 7446-19-7 RNZCSKGULNFAMC-UHFFFAOYSA-L - Active Moieties
Name Kind UNII CAS InChI Key Zinc cation ionic 13S1S8SF37 23713-49-7 PTFCDOFLOPIGGS-UHFFFAOYSA-N - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Micro Zn Solution 5 mg / mL Intravenous Sandoz Canada Incorporated 1992-12-31 Not applicable Canada 
Micro Zn Solution 1 mg / mL Intravenous Sandoz Canada Incorporated 1992-12-31 Not applicable Canada Zin Pro Tab 90mg Tablet 90 mg / tab Oral Professional Health Products 1991-12-31 1997-08-22 Canada Zinc Sulfate Injection, solution 1 mg/1mL Intravenous AMERICAN REGENT, INC. 1990-09-30 2021-05-31 US 
Zinc Sulfate Injection, solution 5 mg/1mL Intravenous AMERICAN REGENT, INC. 1990-09-30 2021-02-28 US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Anu-aide - Ont Top 0.5% Ointment .5 % Topical Technilab Pharma Inc. 1997-07-30 2005-08-05 Canada Ascazin Capsules (Zinc 50.96mg) Capsule Oral UNIMED SDN BHD 2020-09-08 Not applicable Malaysia 
EYE GLO RELIEF EYE DROPS 0.25%w/v Solution / drops 0.25 %w/v Ophthalmic DUOPHARMA (M) SDN. BHD. 2021-12-02 Not applicable Malaysia EYE GLO RELIEF EYE DROPS 0.25%w/v Solution / drops 0.25 % Ophthalmic Duopharma Marketing Sdn. Bhd. 2020-09-08 2021-12-12 Malaysia Zinc Liquid- 15mg/5ml Liquid 15 mg / 5 mL Oral Metagenics, Inc. 1997-02-01 2008-08-28 Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image 8-symptom Relief Zinc sulfate (0.25 % w/v) + Tetrahydrozoline hydrochloride (0.05 % w/v) Solution Ophthalmic TEVA Canada Limited 2016-07-22 Not applicable Canada Adeks - Dps Zinc sulfate (5 mg / mL) + Ascorbic acid (45 mg / mL) + Beta carotene (1 mg / mL) + Biotin (15 mcg / mL) + Cyanocobalamin (4 mcg / mL) + Nicotinamide (6 mg / mL) + Panthenol (3 mg / mL) + Phylloquinone (0.1 mg / mL) + Pyridoxine hydrochloride (0.6 mg / mL) + Riboflavin (0.6 mg / mL) + Thiamine (0.5 mg / mL) + Vitamin A palmitate (1500 unit / mL) + Vitamin D (400 unit / mL) + Vitamin E (40 unit / mL) Solution / drops Oral Axcan Pharma 1995-12-31 2007-10-01 Canada Allergy Eye Drops Zinc sulfate (0.25 % w/v) + Tetrahydrozoline hydrochloride (0.05 % w/v) Solution Ophthalmic Kc Pharmaceuticals, Inc. Not applicable Not applicable Canada Allergy Eye Drops Zinc sulfate (0.25 % w/v) + Tetrahydrozoline hydrochloride (0.05 % w/v) Solution Ophthalmic TEVA Canada Limited 2007-05-23 Not applicable Canada Allergy Eye Drops Zinc sulfate (0.25 %) + Tetrahydrozoline hydrochloride (0.05 %) Solution / drops Ophthalmic Alcon, Inc. 2005-06-24 2009-04-24 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image MEDIZINC SURUP 100 ML Zinc sulfate (100 ml) Syrup Oral CASEL ECZACI CAHİT SELİMOĞLU İLAÇ SAN. VE TİC. LTD. ŞTİ. 2013-01-29 Not applicable Turkey 
Multitrace -4 Zinc sulfate heptahydrate (22 mg/1mL) + Chromic chloride hexahydrate (51.3 ug/1mL) + Cupric sulfate pentahydrate (3.93 mg/1mL) + Manganese sulfate (1.54 mg/1mL) Injection, solution, concentrate Intravenous AMERICAN REGENT, INC. 1993-11-29 Not applicable US Multitrace -4 Zinc sulfate heptahydrate (22 mg/1mL) + Chromic chloride hexahydrate (51.3 ug/1mL) + Cupric sulfate pentahydrate (3.93 mg/1mL) + Manganese sulfate (1.54 mg/1mL) Injection, solution, concentrate Intravenous AMERICAN REGENT, INC. 1993-12-07 Not applicable US Multitrace -4 Pediatric Zinc sulfate heptahydrate (4.39 mg/1mL) + Chromic chloride hexahydrate (5.12 ug/1mL) + Cupric sulfate pentahydrate (0.4 mg/1mL) + Manganese sulfate (77 ug/1mL) Injection, solution, concentrate Intravenous AMERICAN REGENT, INC. 1993-12-09 Not applicable US Multitrace-4 Zinc sulfate heptahydrate (4.39 mg/1mL) + Chromic chloride hexahydrate (20.5 ug/1mL) + Cupric sulfate pentahydrate (1.57 mg/1mL) + Manganese sulfate (0.308 mg/1mL) Injection, solution Intravenous AMERICAN REGENT, INC. 1994-02-17 Not applicable US
Categories
- ATC Codes
- C05AX04 — Zinc preparations
- C05AX — Other agents for treatment of hemorrhoids and anal fissures for topical use
- C05A — AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
- C05 — VASOPROTECTIVES
- C — CARDIOVASCULAR SYSTEM
- A12CB — Zinc
- A12C — OTHER MINERAL SUPPLEMENTS
- A12 — MINERAL SUPPLEMENTS
- A — ALIMENTARY TRACT AND METABOLISM
- Drug Categories
- Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use
- Alimentary Tract and Metabolism
- Astringents
- Blood and Blood Forming Organs
- Blood Substitutes and Perfusion Solutions
- Dermatologicals
- Electrolyte Solutions
- I.V. Solution Additives
- Metal cations
- Metal divalent cations
- Mineral Supplements
- Minerals
- Misc. Skin and Mucous Membrane Agents
- Replacement Preparations
- Sulfates
- Sulfur Acids
- Sulfur Compounds
- Sulfuric Acids
- Vasoprotectives
- Zinc Compounds
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as transition metal sulfates. These are inorganic compounds in which the largest oxoanion is sulfate, and in which the heaviest atom not in an oxoanion is a transition metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Transition metal oxoanionic compounds
- Sub Class
- Transition metal sulfates
- Direct Parent
- Transition metal sulfates
- Alternative Parents
- Inorganic salts / Inorganic oxides
- Substituents
- Inorganic oxide / Inorganic salt / Transition metal sulfate
- Molecular Framework
- Not Available
- External Descriptors
- zinc molecular entity, metal sulfate (CHEBI:35176)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 0J6Z13X3WO
- CAS number
- 7733-02-0
- InChI Key
- NWONKYPBYAMBJT-UHFFFAOYSA-L
- InChI
- InChI=1S/H2O4S.Zn/c1-5(2,3)4;/h(H2,1,2,3,4);/q;+2/p-2
- IUPAC Name
- zinc(2+) sulfate
- SMILES
- [Zn++].[O-]S([O-])(=O)=O
References
- General References
- External Links
- PubChem Compound
- 24424
- PubChem Substance
- 310265204
- ChemSpider
- 22833
- 39954
- ChEBI
- 35176
- ChEMBL
- CHEMBL1200929
- PharmGKB
- PA451971
- Wikipedia
- Zinc_sulfate
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Prevention Effect of Drugs / Preterm, Infant / Zinc Deficiency Disease 1 4 Completed Prevention Immunosuppression / Status;Splenectomy / Thalassemia 1 4 Completed Treatment Acute Diarrhea / Acute Gastroenteritis 1 4 Completed Treatment Coronavirus Disease 2019 (COVID‑19) 1 4 Completed Treatment Glossitis, Benign Migratory 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution / drops Oral Solution Ophthalmic Drug delivery system Cutaneous Ointment Rectal; Topical Ointment Topical .5 % Suppository Rectal Capsule Oral Syrup Oral 30 mg/5ml Suspension Oral Tablet, effervescent Oral 25 mg/1 Spray Topical Liquid Topical Tablet, effervescent Oral Solution Oral 200 mg Solution / drops Ophthalmic 0.25 %w/v Solution / drops Ophthalmic 0.25 % Syrup Oral Syrup Oral 400 mg Syrup Oral 40000000 mg Capsule, liquid filled Oral 2000000 mg Solution Oral 10 mg Solution Oral 1000000 mg Ointment Rectal Tablet, coated Oral 150 mcg Gel Topical Solution Intravenous Capsule Oral 5 mg / cap Syrup Oral 100 ml Liquid Intravenous Solution Intravenous 1 mg / mL Solution Intravenous 5 mg / mL Injection, solution, concentrate Intravenous Injection, solution Intravenous Solution Oral Liquid Oral Syrup Oral 15 mg/5ml Tablet Oral Ointment Topical Emulsion Intravenous Emulsion Intravenous 13.000 g Injection, emulsion Intravenous Emulsion Parenteral Capsule, liquid filled Oral Capsule Oral Capsule, gelatin coated Oral Syrup Oral 20 MG/5ML Tablet, film coated Oral Granule Oral Syrup Oral Tablet Oral 90 mg / tab Liquid Oral 15 mg / 5 mL Tablet Oral 5 mg Liquid Oral 5 mg / mL Injection, solution Intravenous 1 mg/1mL Injection, solution Intravenous 5 mg/1mL Solution / drops; suspension / drops Tablet, soluble Oral 54.9 MG Tablet, soluble Oral 54.89 MG Liquid Oral 13.5 mg / 10 mL Tablet, effervescent Oral Tablet, effervescent Oral 50 mg Syrup Oral 25 mg/5ml Syrup Oral 30 mg Tablet Oral 30 mg Solution / drops Ophthalmic Capsule Oral 50 mg Tablet Oral Tablet, sugar coated Oral 88 mg Tablet, effervescent Oral 88 mg Tablet, effervescent Oral 69 mg Capsule, liquid filled Oral 20 mg Tablet, effervescent Oral 44 mg Tablet, sugar coated Oral 44 mg Tablet, film coated Tablet, soluble Oral Tablet, film coated 25 mg Capsule Oral 25 mg Tablet, coated Oral 25 mg Tablet Oral 25 mg Liquid Ophthalmic Tablet, film coated - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -0.84 Chemaxon pKa (Strongest Acidic) -3 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 80.26 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 11.53 m3·mol-1 Chemaxon Polarizability 5.81 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-08fr-0900000000-72ac9ed930d23dbb4017 - Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at November 17, 2015 17:46 / Updated at February 20, 2024 23:55